BCM
TTPH

BlueCrest Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

BlueCrest Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,344
Closed -$270K – 1217
2015
Q4 		$270K Buy
+1,344
New +$268K 0.01% 757

Other funds holding TTPH

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's TTPH Position: Q1 2016 in Review

BlueCrest Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2016, closing a stake of 1,344 shares — an estimated $270K sold.

BlueCrest Capital Management first reported a position in TTPH in Q4 2015 and held it in 1 quarter. The position peaked at $270K in Q4 2015. 101 funds tracked by Wall St. Rank hold TTPH as of Q1 2016.

  • BlueCrest Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,344 Tetraphase Pharmaceuticals, Inc. shares in Q1 2016, an estimated $270K.
  • BlueCrest Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • BlueCrest Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $270K in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2016.

Based on BlueCrest Capital Management's 13F filing for Q1 2016, filed 3 May 2016.